Many people living with digestive symptoms have come across the term “leaky gut” online, often linked to bloating, fatigue, skin problems, or food sensitivities. For people with inflammatory bowel disease (IBD), the idea can feel especially relevant, since gut lining damage is a genuine part of their condition. But the term is used very differently in wellness culture than it is in gastroenterology research, and that gap is worth untangling.
What is “leaky gut”?
In scientific terms, “leaky gut” refers to increased intestinal permeability, meaning the lining of the gut allows more substances to pass through it than usual. The gut wall is normally a tightly controlled barrier, letting nutrients through while keeping bacteria, toxins, and undigested food particles out of the bloodstream. When this barrier becomes less selective, it is described as having increased permeability. This is a measurable physiological state, studied using specific laboratory tests, not a stand-alone diagnosis that explains unrelated symptoms across the body.
Why it matters for gut inflammation
The gut lining sits between two systems, the outside world (through food and the microbiome, the trillions of bacteria and other microbes living in the digestive tract) and the immune system underneath it. When the barrier is intact, the immune system is exposed to a controlled, low level of bacterial material, which helps keep it calm. When the barrier becomes more permeable, bacterial fragments and other particles can reach immune cells more easily, triggering inflammatory signalling. In people with IBD, this matters because increased permeability appears to occur alongside active inflammation, and the two seem to reinforce one another rather than one simply causing the other.
Key mechanisms
Tight junctions and the epithelial barrier
The gut lining is made of a single layer of epithelial cells held together by structures called tight junctions, protein complexes that seal the gaps between cells. These junctions can open and close in response to signals from the immune system, the microbiome, and dietary factors. In Crohn’s disease and ulcerative colitis, inflammation can loosen these junctions, allowing greater permeability in the areas affected by disease activity.
Zonulin and barrier regulation
Zonulin is a protein involved in regulating tight junction opening. Research, largely from the group that first identified it, suggests zonulin levels rise in some inflammatory and autoimmune conditions, potentially contributing to a more permeable barrier. However, zonulin testing is not yet standardised for routine clinical use, and raised levels do not, by themselves, confirm a diagnosis or explain unrelated symptoms.
The microbiome’s influence
The bacteria living in the gut help maintain the barrier by producing substances such as short-chain fatty acids, which support the health of epithelial cells. An imbalance in the microbiome, sometimes called dysbiosis, has been associated with reduced production of these protective substances and with greater permeability. This relationship appears to run in both directions, since inflammation itself can also disrupt the microbiome.
Permeability in Crohn’s disease and ulcerative colitis
Increased intestinal permeability has been documented in people with IBD, including some first-degree relatives without the condition, which has led researchers to ask whether barrier changes might sometimes precede visible inflammation. Even so, permeability tends to track closely with disease activity, rising during flares and improving as inflammation settles with treatment. This makes it difficult to say that a “leaky gut” is the root cause of IBD rather than one part of a wider inflammatory process.
Separating cause from consequence
Much of the public discussion around leaky gut treats it as an isolated syndrome responsible for a wide range of unconnected symptoms. In the research literature, increased permeability is better understood as one measurable feature within a broader picture involving the immune system, the microbiome, and genetic susceptibility. It is not currently established as a condition that can be diagnosed and treated independently of the underlying disease process.
It is worth remembering that symptoms such as bloating, fatigue, or altered bowel habits do not always mean inflammation is present, and increased permeability cannot be assumed from symptoms alone. Any change in symptoms in someone with IBD should be discussed with their gastroenterology team, since this information does not replace medical assessment or treatment.
Practical Takeaways
- Focus on consistent, medically guided management of IBD rather than seeking a single explanation for all symptoms.
- Be cautious of supplements or products marketed specifically to “heal leaky gut,” as this is not a recognised standalone diagnosis.
- Support the gut lining through general good nutrition and stable eating patterns, ideally guided by a dietitian familiar with IBD.
- Keep track of symptoms and flares and report changes to your IBD team rather than self-diagnosing permeability issues.
- Understand that reducing inflammation through prescribed treatment is currently the most evidence-based way to support barrier function in IBD.
Conclusion
Increased intestinal permeability is a real, measurable phenomenon that plays a part in the inflammatory processes seen in Crohn’s disease and ulcerative colitis. It is closely tied to immune activity and the microbiome, rising and falling alongside disease activity rather than existing as an independent syndrome. The popular idea of “leaky gut syndrome” oversimplifies this relationship and can lead people away from evidence-based care. Long-term stability in IBD comes from consistent medical management and attention to overall gut health, not from treating permeability as a disease in its own right.
References
- Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91(1):151-175. doi:10.1152/physrev.00003.2008
- Michielan A, D’Incà R. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm. 2015;2015:628157. doi:10.1155/2015/628157
- Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol. 2017;14(1):9-21. doi:10.1038/nrgastro.2016.169
- Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019;68(8):1516-1526. doi:10.1136/gutjnl-2019-318427
- Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9(11):799-809. doi:10.1038/nri2653
- Vindigni SM, Zisman TL, Suskind DL, Damman CJ. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therap Adv Gastroenterol. 2016;9(4):606-625. doi:10.1177/1756283X16644242
- Salvo Romero E, Alonso Cotoner C, Pardo Camacho C, Casado Bedmar M, Vicario M. The intestinal barrier function and its involvement in digestive disease. Rev Esp Enferm Dig. 2015;107(11):686-696.
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.